Wall Street predicts that these rapidly expanding growth stocks will generate outsized gains this year.
Amicus Therapeutics: Q3 Earnings Snapshot
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates...
Stocks that traded heavily or had substantial price changes on Friday: Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall
Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth,...
Amicus Therapeutics: Q2 Earnings Snapshot
Companies in The news Are: VSH,COHRICL,FOLD
Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -38.46% and 5.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics: Q1 Earnings Snapshot